Yizhou Dong named Ohio State early career innovator of the year


March 6, 2018

yizhou in lab
News Story Content

Yizhou Dong, assistant professor of Pharmaceutics and Pharmaceutical Chemistry was named the 2017 Ohio State Early Career Innovator of the Year. The award was announced and presented to Dr. Dong on March 6, 2018, at the university’s annual state of research address.

The Early Career Innovator of the Year award recognizes an Ohio State researcher who is working to promote commercialization of university intellectual property through invention disclosures filed, patents applied for and/or received, technologies licensed or spinoff companies formed. These activities support economic development in the central Ohio region, and serve to attract companies that create a base of operations within the state. The award was eligible for an assistant or early associate professor (if a faculty member), or someone who has been at Ohio State no more than 10 years (if a staff member).

Dong joined the College of Pharmacy’s faculty in 2014. He is also a member of the globally recognized Translational Therapeutics team at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Along with his research group, Dr. Dong is devoted to drug discovery and delivery for the treatment of cancer, as well as inherited genetic disorders and infectious diseases. The team integrates their specialty in pharmaceutics, pharmaceutical chemistry, biomedical engineering, materials formulation, and animal studies to design novel therapeutic medicines and uncover their mechanisms of actions. Their ultimate goal is to translate scientific results and technological inventions into more effective treatments, resulting in more fulfilled lives of all individuals.

Since arriving at Ohio State, Dr. Dong has filed over a dozen invention disclosures and has 10 provisional patents pending. His technologies have garnered commercial interest resulting in the out-licensing of his aminoacid-, peptide- and polypeptide-lipid technologies to two companies. Moreover, he has registered a start-up company with the intention of seeking SBIR funding to translate his findings into improved patient outcomes.

Dong was also recently recognized by Columbus Business First in the Class of 2017 “Forty under 40,” a program that recognizes young professionals who are making great strides in shaping our community’s future.